NEW YORK, June 28, 2016 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Regulus Therapeutics Inc. ("Regulus" or the Company) (NASDAQ: RGLS). Such investors are advised to contact Robert S. Willoughby at email@example.com or 888-476-6529, ext. 9980.
The investigation concerns whether Regulus and certain of its officers and/or directors have violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934.
On June 27, 2016, Regulus announced that it had received verbal notice from the U.S. Food and Drug Administration ("FDA") that the FDA had placed the Company's investigational new drug for the treatment of chronic hepatitis C virus infection on clinical hold after a second serious adverse event of jaundice was reported.
On this news, Regulus stock fell as much as $2.71, or more than 54%, to $2.30 after hours on June 27, 2016.
The Pomerantz Firm, with offices in New York, Chicago, Florida, and Los Angeles, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 80 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomerantzlaw.com
Robert S. Willoughby
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/shareholder-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-regulus-therapeutics-inc--rgls-300291228.html
SOURCE Pomerantz LLP